Get the Stockscreener App
5.41
2.85%
0.15
Sight Sciences Inc stock is traded at $5.41, with a volume of 503.62K.
It is up +2.85% in the last 24 hours and down -11.60% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$5.26
Open:
$5.24
24h Volume:
503.62K
Relative Volume:
1.84
Market Cap:
$286.04M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-4.7456
EPS:
-1.14
Net Cash Flow:
$-47.98M
1W Performance:
+4.44%
1M Performance:
-11.60%
6M Performance:
+45.04%
1Y Performance:
+119.03%
1-Day Range:
$5.154
$5.54
1-Week Range:
$5.04
$5.66
52-Week Range:
$2.03
$9.2362
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
5.41 | 278.11M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-08-25 | Upgrade | Lake Street | Hold → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Sight Sciences sees FY26 revenue $82M-$88M, consensus $86.11M - TipRanks
Sight Sciences Q4 2025 Earnings Call Transcript - MarketBeat
Sight Sciences Q4 Earnings Call Highlights - MarketBeat
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Sight Sciences (SGHT) Q4 2025 Earnings Transcript - AOL.com
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Sight Sciences reports Q4 EPS (8c), consensus (14c) - TipRanks
Earnings call transcript: Sight Sciences beats Q4 2025 forecasts, stock rises - Investing.com
Sight Sciences Q4 Loss Narrows, Revenue Rises - marketscreener.com
Sight Sciences Inc. (SGHT) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Sight Sciences (NASDAQ:SGHT) Issues Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
Sight Sciences Q4 Earnings Assessment - Benzinga
Sight Sciences Posts Q4 Growth, Issues 2026 Outlook - TipRanks
SGHT: OMNI and TearCare drive innovation in eyecare, targeting large, underserved markets - TradingView
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance - The Manila Times
Sight Sciences (SGHT) outlines interventional glaucoma and dry eye growth plan - Stock Titan
Sight Sciences (NASDAQ: SGHT) narrows 2025 loss and targets 6–14% growth - Stock Titan
SGHT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Uncovering Potential: Sight Sciences's Earnings Preview - Benzinga
5 Analysts Assess Sight Sciences: What You Need To Know - Benzinga
Stifel Nicolaus Issues Positive Forecast for Sight Sciences (NASDAQ:SGHT) Stock Price - MarketBeat
Stifel raises Sight Sciences stock price target on TearCare survey - Investing.com
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
SGHT SEC FilingsSight Sciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sight Sciences (NASDAQ:SGHT) Has Debt But No Earnings; Should You Worry? - 富途牛牛
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Sight Sciences, Inc. (SGHT) Projected to Surpass Earnings Predictions: Will the Share Price Rise? - Bitget
Sight Sciences (SGHT) Projected to Post Quarterly Earnings on Wednesday - Defense World
[Form 4] Sight Sciences, Inc. Insider Trading Activity - Stock Titan
Should you avoid Sight Sciences Inc. stock right nowJuly 2025 Rallies & Precise Buy Zone Identification - mfd.ru
Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - The Manila Times
Sight Sciences, Inc. Scheduled to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Quiver Quantitative
Will Sight Sciences Inc. stock rally after Fed decisionsJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - mfd.ru
Why Sight Sciences Inc. stock is recommended by analystsWeekly Stock Summary & Accurate Trade Setup Notifications - mfd.ru
Will Sight Sciences Inc. stock recover after earningsQuarterly Trade Summary & Free Risk Controlled Daily Trade Plans - mfd.ru
Can Sight Sciences Inc. be recession proof2025 Trade Ideas & Fast Entry Momentum Alerts - mfd.ru
KCK LTD. Adjusts Holdings in Sight Sciences Inc: A Strategic Por - GuruFocus
Chart Watch: Will Sight Sciences Inc outperform tech stocks2025 Top Decliners & Stepwise Swing Trade Plans - baoquankhu1.vn
Sight Sciences: Investor Attention Shifts to 2026 Milestones - AD HOC NEWS
Aug Action: Is Sight Sciences Inc on track to beat earningsBear Alert & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Market Catalysts: Is Sight Sciences Inc subject to activist investor interest2025 Pullback Review & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Sight Sciences Extends Menlo Park Headquarters Lease Agreement - The Globe and Mail
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sight Sciences extends Menlo Park headquarters lease with rent abatement period By Investing.com - Investing.com India
Sight Sciences extends Menlo Park headquarters lease with rent abatement period - Investing.com Canada
Sight Sciences (NASDAQ:SGHT) Raised to “Strong-Buy” at William Blair - Defense World
Sight Sciences (NASDAQ:SGHT) Raised to Strong-Buy at William Blair - MarketBeat
William Blair resumes Sight Sciences stock with Outperform rating By Investing.com - Investing.com Australia
William Blair resumes Sight Sciences stock with Outperform rating - Investing.com
Sight Sciences (NASDAQ:SGHT) and Vaso (OTCMKTS:VASO) Head to Head Survey - Defense World
Sight Sciences (SGHT) chief legal officer sells $41,758 in stock By Investing.com - Investing.com UK
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):